Isogenica was formed in December 2000 to develop and commercialize innovative in vitro molecular evolution technologies. The company has its research facility at the Babraham Research Campus, Cambridge UK. Isogenica’s core technology, CIS display, can be applied to the discovery of new antibody, peptide and polypeptide drug candidates, to the discovery of high specificity diagnostic compounds and to the isolation of target validation and other research reagents, purification reagents and environmental detection reagents.

Acquired Companies: Karyon-CTT